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LETTERS TO THE EDITORDifferences in the
Epidemiology of Rare EGFR
Mutations in Different
PopulationsIn Response:
We thank Elghissassi et al. for their comment on our
study.1 This is a great opportunity to further discuss the
differences in the epidemiology of rare epidermal
growth factor receptor gene (EGFR) mutations in
different patient populations.
The complete coverage of exons 18 to 21 and the
EGFR analysis in patients with Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations—as we all agree—
could very well be one reason for the increased rate of
rare EGFR mutations. Importantly, it seems that smoking
status can also have a great—and indeed patient popu-
lation–dependent—impact on the rate of rare EGFR
mutations. Unfortunately, in Hungary as well as in our
patient cohort, the number of current smokers is very
high, which could lead to enrichment for rare
EGFR mutations. Interestingly, unlike in white cohorts,
the rare EGFR mutations in Asian populations do not
seem to be associated with smoking. Notably, the ﬁnd-
ings of Errihani et al. suggest that the epidemiology of
such mutations in Morocco has greater resemblance to
that in the Asian population than to that in white study
cohorts.2
We cannot emphasize enough that the lack of
identical methods makes side-by-side comparison of
the different studies very difﬁcult. A number of com-
mercial mutation analysis methods provide very high
sensitivity, but only for a preselected set of molecular
alterations that might enrich for classical EGFR mu-
tations.3 In contrast, direct (Sanger) sequencing has a
lower sensitivity but can identify novel mutations.
Indeed, a number of rare mutations described in our
study were reported in lung adenocarcinoma for the
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possibility has been discussed in a previous exchange
of comments.4,5
One of the major ﬁndings of our study is that the
absolute number of rare EGFR mutations in certain
patient populations can be rather high, and thus, their
clinical relevance needs to be studied further. More-
over, the term rare EGFR mutation describes a very
heterogeneous group of molecular alterations, and as
a result, the clinical relevance of each individual mu-
tation needs to be evaluated separately. Therefore,
reporting the clinical relevance and epidemiology of
all EGFR mutations for different patient populations
will lead to more accurate and evidence-based therapy
decisions in the future.
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